Cell‑free DNA and chemoembolization in patients with liver metastases from colorectal cancer

Boysen,Anders Kindberg; Jensen,Martin; Nielsen,Dennis Tønner; Mortensen,Frank Viborg; Sørensen,Brita Singers; Jensen,Anni Ravnsbæk; Spindler,Karen‑Lise

doi:10.3892/ol.2018.8925

Cell‑free DNA and chemoembolization in patients with liver metastases from colorectal cancer

Authors:
- Anders Kindberg Boysen
- Martin Jensen
- Dennis Tønner Nielsen
- Frank Viborg Mortensen
- Brita Singers Sørensen
- Anni Ravnsbæk Jensen
- Karen‑Lise Spindler
View Affiliations

Affiliations: Department of Oncology, Aarhus University Hospital, 8000 Aarhus C, Denmark, Department of Radiology, Aarhus University Hospital, 8000 Aarhus C, Denmark, Department of Surgical Gastroenterology, Aarhus University Hospital, 8000 Aarhus C, Denmark, Department of Experimental Clinical Oncology, Aarhus University Hospital, 8000 Aarhus C, Denmark
Published online on: June 7, 2018 https://doi.org/10.3892/ol.2018.8925
Pages: 2654-2660

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Transarterial chemoembolization with irinotecan loaded beads (DEBIRI‑TACE) represents an investigative treatment option for patients with metastatic colorectal cancer (mCRC). The present study examined DEBIRI‑TACE with concomitant mFOLOFX6‑bevacizumab as a first‑line treatment for mCRC and explored the clinical value of circulating cell‑free DNA (cfDNA). Patients with limited mCRC of the liver who had not been treated with chemotherapy received up to 4 biweekly DEBIRI‑TACE treatments. The endpoints examined included the response rate, survival, toxicity and translational analysis. Due to toxicity and lack of feasibility, the study closed prematurely. Total cfDNA was measured with a direct fluorescent assay. Between December 2012 and February 2014, 14 patients underwent a total of 49 DEBIRI‑TACE treatments. With a median follow‑up of 1.7 years, the median progression free survival and overall survival (OS) were 240 days [95% confidence interval (CI): 161‑357] and 522 days (95% CI: 174‑1,054), respectively. The response rate was 50%. Twelve patients experienced grade 3 toxicity or above. Dynamics of cfDNA showed biological variations in relation to therapy. To conclude, the present results indicated a response rate of 50% and median OS of 522 days for 14 patients with mCRC undergoing DEBIRI‑TACE, but unacceptable toxicity and lack of feasibility with the applied schedule. The findings suggest that the level of cfDNA may be associated with the disease course, response to treatment and outcome. Trial registration: The European Clinical Trials database (EudraCT no. 2012‑000987‑11) at 05‑14‑2012.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: CCancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E389. 2015. View Article : Google Scholar : PubMed/NCBI
2	Weiss L, Grundmann E, Torhorst I, Hartveit F, Moberg I, Ider M, Fenoglio-Preiser CM, Napier J, Horne CH, Lopez MJ, et al: Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 150:195–203. 1986. View Article : Google Scholar : PubMed/NCBI
3	Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larsson DW, Grothey A, Vauthey JN, Nagorney DM and McWilliams RR: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 27:3677–3683. 2009. View Article : Google Scholar : PubMed/NCBI
4	Gillams AR and Lees WR: Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 19:1206–1213. 2009. View Article : Google Scholar : PubMed/NCBI
5	Fode MM and Høyer M: Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol. 114:155–160. 2015. View Article : Google Scholar : PubMed/NCBI
6	Yamada R, Sato M, Kawabata K, Nakatsuka H, Nakamura K and Takashima S: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 148:397–401. 1983. View Article : Google Scholar : PubMed/NCBI
7	Aliberti C, Tilli M, Benea G and Fiorentini G: Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: Preliminary results. Anticancer Res. 26:3793–3795. 2006.PubMed/NCBI
8	Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giodani P, Mambrini A, Montagnani F, Alessandroni P, Catalano V and Coschiera P: IIntra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: Final results of a phase III study. Anticancer Res. 32:1387–1395. 2012.PubMed/NCBI
9	Martin RC II, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, Kelly LR, Garcia-Monaco RD, Sharma VR, Crocenzi TS and Strasberg SM: Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 121:3649–3658. 2015. View Article : Google Scholar : PubMed/NCBI
10	van Cutsem E, Cervantes A, Adam R, Sobrero A, van Krieken JH, Aderka D, Aguilar Aranda E, Bardelli A, Benson A, Bodoky G, et al: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
11	Spindler KL, Appelt A, Pallisgaard N, Andersen RF, Brandslund I and Jakobsen A: Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. Int J Cancer. 135:2984–2991. 2014. View Article : Google Scholar : PubMed/NCBI
12	Mandel P and Metasis P: Les acides nucléiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil. 142:241–243. 1948.(In Undetermined Language). PubMed/NCBI
13	Leon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:646–650. 1977.PubMed/NCBI
14	Boysen AK, Wettergren Y, Sorensen BS, Taflin H, Gustavson B and Spindler KG: Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer. Tumour Biol. 39:10104283177309762017. View Article : Google Scholar : PubMed/NCBI
15	Spindler KG, Boysen AK, Pallisgård N, Johansen JS, Tabernero J, Sørensen MM, Jensen BV, Hansen TF, Sefrioui D, Andersen RF, et al: Cell-free DNA in metastatic colorectal cancer: A systematic review and meta-analysis. Oncologist. 22:1049–1055. 2017. View Article : Google Scholar : PubMed/NCBI
16	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargant D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
17	Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, . Version 3.0. DCTD, NCI, NIH, DHHS March 31. 2003.http://ctep.cancer.govAugust 9–2006
18	Price DD, McGrath PA, Rafii A and Buckingham B: The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 17:45–56. 1983. View Article : Google Scholar : PubMed/NCBI
19	Goldshtein H, Hausmann MJ and Douvdevani A: A rapid direct fluorescent assay for cell-free DNA quantification in biological fluids. Ann Clin Biochem. 46:488–494. 2009. View Article : Google Scholar : PubMed/NCBI
20	Schou JV, Larsen FO, Sørensen BS, Abrates R, Boysen AK, Johansen JS, Jensen BV, Nielsen DL and Spindler KL: Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer. Ann Oncol. 29:610–615. 2018. View Article : Google Scholar : PubMed/NCBI
21	Eichler K, Zangus S, Mack MG, Hammerstring R, Gruber-Rouh T, Galluc C and Vogl TJ: First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). Int J Oncol. 41:1213–1220. 2012. View Article : Google Scholar : PubMed/NCBI
22	Fiorentini G, Aliberti C, Turrisi G, del Conte A, Rossi S, Benea G and Giovanis P: IIntraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study. In Vivo. 21:1085–1091. 2007.PubMed/NCBI
23	Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, et al: Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 371:1609–1618. 2014. View Article : Google Scholar : PubMed/NCBI
24	Tie J, Kinde I, Wang Y, Wong HL, Roebort J, Christie M, Tacey M, Wong R, Singh M, Karapetis CS, et al: Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 26:1715–1722. 2015. View Article : Google Scholar : PubMed/NCBI
25	Reinert T, Schøler L, Thomsen R, Tobiasen H, Vang S, Nordentoft I, Lamy P, Kannerup AS, Mortensen FV, Stribolt K, et al: Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 65:625–634. 2016. View Article : Google Scholar : PubMed/NCBI